UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Guidelines on the management of abnormal liver blood tests

Gut, 2018-01, Vol.67 (1), p.6-19

2018

Volltextzugriff (PDF)

A systematic review and meta-analysis of community and primary-care-based hepatitis C testing and treatment services that employ direct acting antiviral drug treatments

BMC health services research, 2019-10, Vol.19 (1), p.765-765, Article 765

2019

Volltextzugriff (PDF)

Increased risk of chronic kidney disease and mortality in a cohort of people diagnosed with metabolic dysfunction associated steatotic liver disease with hepatic fibrosis

PloS one, 2024-04, Vol.19 (4), p.e0299507-e0299507

2024

Volltextzugriff (PDF)

Experimental Nonalcoholic Steatohepatitis and Liver Fibrosis Are Ameliorated by Pharmacologic Activation of Nrf2 (NF-E2 p45-Related Factor 2)

Cellular and molecular gastroenterology and hepatology, 2018-01, Vol.5 (3), p.367-398

2018

Volltextzugriff (PDF)

Drug‐Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles

Clinical pharmacology and therapeutics, 2019-07, Vol.106 (1), p.245-253

2019

Volltextzugriff (PDF)

Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause‐specific outcomes

Hepatology (Baltimore, Md.), 2015-08, Vol.62 (2), p.355-364

2015

Volltextzugriff (PDF)

Thrombocytosis and abnormal liver enzymes: A trigger for investigation of underlying malignancy

PloS one, 2022-04, Vol.17 (4), p.e0267124-e0267124

2022

Volltextzugriff (PDF)

Mixed-methods evaluation of point-of-care hepatitis C virus RNA testing in a Scottish prison

BMJ open, 2023-04, Vol.13 (4), p.e068604

2023

Volltextzugriff (PDF)

Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis

Free radical biology & medicine, 2010-01, Vol.48 (2), p.357-371

2010

Volltextzugriff (PDF)

Optimal ALT threshold for the automated diagnosis of MASLD: A population-based study using iLFT

Annals of hepatology, 2024-03, Vol.29 (2), p.101280-101280, Article 101280

2024

Volltextzugriff (PDF)

Transformation of identity in substance use as a pathway to recovery and the potential of treatment for hepatitis C: a systematic review protocol

BMJ open, 2022-02, Vol.12 (2), p.e049713-e049713

2022

Volltextzugriff (PDF)

Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population

Journal of hepatology, 2017-01, Vol.66 (1), p.19-27

2017

Volltextzugriff (PDF)

Laying the foundations for hepatitis C elimination: evaluating the development and contribution of community care pathways to diagnostic efforts

BMC public health, 2023-01, Vol.23 (1), p.54-9, Article 54

2023

Volltextzugriff (PDF)

Intelligent Liver Function Testing (iLFT): An Intelligent Laboratory Approach to Identifying Chronic Liver Disease

Diagnostics (Basel), 2024-05, Vol.14 (9), p.960

2024

Volltextzugriff (PDF)

Future destinations and social inclusion scoping review: how people cured of hepatitis C (HCV) using direct- acting antiviral drugs progress in a new HCV-free world

Substance abuse treatment, prevention and policy, 2022-06, Vol.17 (1), p.45-45, Article 45

2022

Volltextzugriff (PDF)

A multistakeholder approach to innovations in NAFLD care

Communications medicine, 2023-01, Vol.3 (1), p.1-1, Article 1

2023

Volltextzugriff (PDF)

Study protocol: a multicentre, open-label, parallel-group, phase 2, randomised controlled trial of autologous macrophage therapy for liver cirrhosis (MATCH)

BMJ open, 2021-11, Vol.11 (11), p.e053190-e053190

2021

Volltextzugriff (PDF)

Enhanced liver fibrosis (ELF) score predicts hepatic decompensation and mortality

JHEP reports, 2024-06, Vol.6 (6), p.101062-101062, Article 101062

2024

Volltextzugriff (PDF)

Long-term risk factors for developing Barrett’s oesophagus in patients with gastro-oesophageal reflux disease: a longitudinal cohort study

BMJ open gastroenterology, 2024-03, Vol.11 (1), p.e001307

2024

Volltextzugriff (PDF)

The serum proteome of nonalcoholic fatty liver disease: A multimodal approach to discovery of biomarkers of nonalcoholic steatohepatitis

Journal of gastroenterology and hepatology, 2014-10, Vol.29 (10), p.1839-1847

2014

Volltextzugriff (PDF)

Reaching mEthadone users Attending Community pHarmacies with HCV: an international cluster randomised controlled trial protocol (REACH HCV)

BMJ open, 2020-08, Vol.10 (8), p.e036501

2020

Volltextzugriff (PDF)

Gamma‐Glutamyl Transferase (γ‐GT) – an old dog with new tricks?

Liver international, 2022-01, Vol.42 (1), p.9-15

2022

Volltextzugriff (PDF)

DOT-C: A cluster randomised feasibility trial evaluating directly observed anti-HCV therapy in a population receiving opioid substitute therapy from community pharmacy

The International journal of drug policy, 2017-09, Vol.47, p.126-136

2017

Volltextzugriff (PDF)

Randomised controlled trial conducted in injecting equipment provision sites to compare the effectiveness of different hepatitis C treatment regimens in people who inject drugs: A Direct obserVed therApy versus fortNightly CollEction study for HCV treatment—ADVANCE HCV protocol study

BMJ open, 2019-08, Vol.9 (8), p.e029516

2019

Volltextzugriff (PDF)

1 – 25 von 544

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(479)
Mit Volltextzugriff
(438)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(540)
Deutsch
(1)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(10)

Menü

Weitere Dienste

Einstellungen

Guidelines on the management of abnormal liver blood tests

A systematic review and meta-analysis of community and primary-care-based hepatitis C testing and treatment services that employ direct acting antiviral drug treatments

Increased risk of chronic kidney disease and mortality in a cohort of people diagnosed with metabolic dysfunction associated steatotic liver disease with hepatic fibrosis

Experimental Nonalcoholic Steatohepatitis and Liver Fibrosis Are Ameliorated by Pharmacologic Activation of Nrf2 (NF-E2 p45-Related Factor 2)

Drug‐Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles

Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause‐specific outcomes

Thrombocytosis and abnormal liver enzymes: A trigger for investigation of underlying malignancy

Mixed-methods evaluation of point-of-care hepatitis C virus RNA testing in a Scottish prison

Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis

Optimal ALT threshold for the automated diagnosis of MASLD: A population-based study using iLFT

Transformation of identity in substance use as a pathway to recovery and the potential of treatment for hepatitis C: a systematic review protocol

Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population

Laying the foundations for hepatitis C elimination: evaluating the development and contribution of community care pathways to diagnostic efforts

Intelligent Liver Function Testing (iLFT): An Intelligent Laboratory Approach to Identifying Chronic Liver Disease

Future destinations and social inclusion scoping review: how people cured of hepatitis C (HCV) using direct- acting antiviral drugs progress in a new HCV-free world

A multistakeholder approach to innovations in NAFLD care

Study protocol: a multicentre, open-label, parallel-group, phase 2, randomised controlled trial of autologous macrophage therapy for liver cirrhosis (MATCH)

Enhanced liver fibrosis (ELF) score predicts hepatic decompensation and mortality

Long-term risk factors for developing Barrett’s oesophagus in patients with gastro-oesophageal reflux disease: a longitudinal cohort study

The serum proteome of nonalcoholic fatty liver disease: A multimodal approach to discovery of biomarkers of nonalcoholic steatohepatitis

Reaching mEthadone users Attending Community pHarmacies with HCV: an international cluster randomised controlled trial protocol (REACH HCV)

ASEPTIC: primary antibiotic prophylaxis using co-trimoxazole to prevent SpontanEous bacterial PeritoniTIs in Cirrhosis—study protocol for an interventional randomised controlled trial

Gamma‐Glutamyl Transferase (γ‐GT) – an old dog with new tricks?

DOT-C: A cluster randomised feasibility trial evaluating directly observed anti-HCV therapy in a population receiving opioid substitute therapy from community pharmacy

Randomised controlled trial conducted in injecting equipment provision sites to compare the effectiveness of different hepatitis C treatment regimens in people who inject drugs: A Direct obserVed therApy versus fortNightly CollEction study for HCV treatment—ADVANCE HCV protocol study

Suchergebnisse filtern